MEA Cardiac Safety Services Market - Industry Trends and Forecast to 2029

Description

List of Tables

Middle East and Africa cardiac safety services market is projected to register a CAGR of 13.7% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2021, the base year of calculation is 2022 and the forecast period is 2022 to 2029.

Market Segmentation:

Middle East and Africa Cardiac Safety Services Market, By Services (ECG/Holter Measurements, Blood Pressure Measurements, In Vitro Cardiac Safety Assessment Services, Cardiovascular Imaging, Real-Time Telemetry Monitoring, Central Over-Read of ECGS, Non-Invasive Cardiac Imaging, Physiologic Stress Testing, Thorough QT Studies, TQT and Exposure Response Modeling, Platelet Aggregation and Other Services), Phase (Phase 1, Phase 2 and Phase 3), Type (Integrated Services and Standalone Services), End User (Pharmaceuticals & Biopharmaceuticals Companies, Contract Research Organizations and Academic and Research Institute) Industry Trends and Forecast to 2029.

Some of the major factors contributing to the growth of the Middle East and Africa cardiac safety services market are:

Increase in the number of clinical trials being conducted

Increase in prevalence of cardiovascular diseases

Market Players:

The key market players for Middle East and Africa cardiac safety services market are listed below:

Koninklijke Philips N.V.

Laboratory Corporation of America Holdings

IQVIA

Medpace

Ncardia

Certara

Eurofins Scientific

SGS SA

1 INTRODUCTION 26

1.1 OBJECTIVES OF THE STUDY 26
1.2 MARKET DEFINITION 26
1.3 OVERVIEW OF MIDDLE EAST & AFRICA CARDIAC SAFETY SERVICES MARKET 26
1.4 LIMITATIONS 27
1.5 MARKETS COVERED 28

2 MARKET SEGMENTATION 30

2.1 MARKETS COVERED 30
2.2 GEOGRAPHICAL SCOPE 31
2.3 YEARS CONSIDERED FOR THE STUDY 32
2.4 CURRENCY AND PRICING 32
2.5 DBMR TRIPOD DATA VALIDATION MODEL 33
2.6 MULTIVARIATE MODELLING 36
2.7 SERVICES LIFELINE CURVE 36
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 37
2.9 DBMR MARKET POSITION GRID 38
2.10 MARKET END USER GRID 40
2.11 VENDOR SHARE ANALYSIS 41
2.12 SECONDARY SOURCES 42
2.13 ASSUMPTIONS 42

3 EXECUTIVE SUMMARY 43

4 PREMIUM INSIGHTS 46

4.1 PORTERS FIVE FORCES 47
4.2 PESTEL ANALYSIS 48

5 EPIDEMIOLOGY 49

5.1 INCIDENCE OF ALL BY GENDER 49
5.2 TREATMENT RATE 50
5.3 MORTALITY RATE 50
5.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL 51

6 INDUSTRY INSIGHT 52

6.1 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES 52
6.2 PATENT ANALYSIS 53
6.3 PATENT FLOW DIAGRAM 54
6.4 KEY PATIENT ENROLLMENT STRATEGIES 54
6.5 PRICING STRATEGY 57

7 MIDDLE EAST & AFRICA CARDIAC SAFETY SERVICES MARKET: REGULATIONS 58

8 MARKET OVERVIEW 61

8.1 DRIVERS 63
- 8.1.1 INCREASE IN THE NUMBER OF CLINICAL TRIALS 63
- 8.1.2 INCREASE IN HEALTHCARE EXPENDITURE AND FUNDING 63
- 8.1.3 INCREASE IN STRATEGIC INITIATIVES BY MAJOR MARKET PLAYERS 64
- 8.1.4 INCREASE IN R&D ACTIVITIES 64
8.2 RESTRAINTS 65
- 8.2.1 HIGH COST OF CARDIAC SAFETY EVALUATION 65
- 8.2.2 STRICT REGULATORY 65
8.3 OPPORTUNITIES: 66
- 8.3.1 INCREASE IN NEW DRUG DEVELOPMENT 66
- 8.3.2 RISE IN THE EXPANSION OF THE CARDIAC SAFETY SERVICES 67
8.4 CHALLENGES 67
- 8.4.1 TIME-CONSUMING PROCEDURE 67
- 8.4.2 LACK OF SKILLED PERSON TO OPERATE DEVICES DURING CARDIAC SAFETY EVALUATION 68

9 MIDDLE EAST & AFRICA CARDIAC SAFETY SERVICES MARKET, BY SERVICES 69

9.1 OVERVIEW 70
9.2 ECG/HOLTER MEASUREMENTS 74
9.3 BLOOD PRESSURE MEASUREMENTS 74
9.4 IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES 75
- 9.4.1 HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS 76
  - 9.4.1.1 1 CONCENTRATIONS 76
  - 9.4.1.2 4 CONCENTRATIONS 76
- 9.4.2 COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) 77
  - 9.4.2.1 3 CONCENTRATIONS 77
  - 9.4.2.2 5 CONCENTRATIONS 77
- 9.4.3 IN VITRO HERG ASSAY 77
- 9.4.4 OTHERS 77
9.5 CARDIOVASCULAR IMAGING 77
9.6 REAL TIME TELEMETRY MONITORING 78
9.7 CENTRAL OVER-READ OF ECGS 79
9.8 NON-INVASIVE CARDIAC IMAGING 79
9.9 PHYSIOLOGIC STRESS TESTING 80
9.10 THOROUGH QT STUDIES 81
9.11 TQT AND EXPOSURE RESPONSE MODELLING 81
9.12 PLATELET AGGREGATION 82
9.13 OTHERS 83

10 MIDDLE EAST & AFRICA CARDIAC SAFETY SERVICES MARKET, BY PHASE 84

10.1 OVERVIEW 85
10.2 PHASE I 88
10.3 PHASE II 88
10.4 PHASE III 89

11 MIDDLE EAST & AFRICA CARDIAC SAFETY SERVICES MARKET, BY TYPE 90

11.1 OVERVIEW 91
11.2 INTEGRATED SERVICES 94
11.3 STANDALONE SERVICES 95

12 MIDDLE EAST & AFRICA CARDIAC SAFETY SERVICES MARKET, BY END USER 96

12.1 OVERVIEW 97
12.2 PHARMACEUTICALS & BIOPHARMACEUTICALS COMPANIES 100
12.3 CONTRACT RESEARCH ORGANIZATIONS 100
12.4 ACADEMIC AND RESEARCH INSTITUTE 101

13 MIDDLE EAST & AFRICA CARDIAC SAFETY SERVICES MARKET, BY REGION 102

13.1 MIDDLE EAST AND AFRICA 103
- 13.1.1 SOUTH AFRICA 111
- 13.1.2 SAUDI ARABIA 114
- 13.1.3 U.A.E. 117
- 13.1.4 ISRAEL 120
- 13.1.5 EGYPT 123
- 13.1.6 REST OF MIDDLE EAST AND AFRICA 126

14 MIDDLE EAST & AFRICA CARDIAC SAFETY SERVICES MARKET: COMPANY LANDSCAPE 127

14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 127

15 COMPANY PROFILE 128

15.1 EUROFINS SCIENTIFIC 128
- 15.1.1 COMPANY SNAPSHOT 128
- 15.1.2 REVENUE ANALYSIS 129
- 15.1.3 COMPANY SHARE ANALYSIS 129
- 15.1.4 PRODUCT PORTFOLIO 129
- 15.1.5 RECENT DEVELOPMENTS 130
  - 15.1.5.1 AGREEMENTS 130
  - 15.1.5.2 ACQUISITION 130
15.2 PPD INC. (SUBSIDIARY OF THERMO FISHER SCIENTIFIC INC) 131
- 15.2.1 COMPANY SNAPSHOT 131
- 15.2.2 REVENUE ANALYSIS 131
- 15.2.3 COMPANY SHARE ANALYSIS 132
- 15.2.4 PRODUCT PORTFOLIO 132
- 15.2.5 RECENT DEVELOPMENT 132
  - 15.2.5.1 INVESTMENT 132
15.3 KONINKLIJKE PHILIPS N.V. 133
- 15.3.1 COMPANY SNAPSHOT 133
- 15.3.2 REVENUE ANALYSIS 133
- 15.3.3 COMPANY SHARE ANALYSIS 134
- 15.3.4 PRODUCT PORTFOLIO 134
- 15.3.5 RECENT DEVELOPMENT 134
  - 15.3.5.1 ACQUISITION 134
15.4 IQVIA 135
- 15.4.1 COMPANY SNAPSHOT 135
- 15.4.2 REVENUE ANALYSIS 135
- 15.4.3 COMPANY SHARE ANALYSIS 136
- 15.4.4 PRODUCT PORTFOLIO 136
- 15.4.5 RECENT DEVELOPMENTS 136
  - 15.4.5.1 ACQUISITION 136
15.5 LABORATORY CORPORATION OF AMERICA HOLDINGS 137
- 15.5.1 COMPANY SNAPSHOT 137
- 15.5.2 REVENUE ANALYSIS 137
- 15.5.3 COMPANY SHARE ANALYSIS 138
- 15.5.4 PRODUCT PORTFOLIO 138
- 15.5.5 RECENT DEVELOPMENTS 138
  - 15.5.5.1 NEW LABORATORY 138
  - 15.5.5.2 ACQUISITION 138
15.6 BANOOK 139
- 15.6.1 COMPANY SNAPSHOT 139
- 15.6.2 PRODUCT PORTFOLIO 139
- 15.6.3 RECENT DEVELOPMENT 139
  - 15.6.3.1 AGREEMENT 139
15.7 BIOTRIAL 140
- 15.7.1 COMPANY SNAPSHOT 140
- 15.7.2 PRODUCT PORTFOLIO 140
- 15.7.3 RECENT DEVELOPMENT 140
  - 15.7.3.1 NEW CENTER OPENING 140
15.8 CELERION 141
- 15.8.1 COMPANY SNAPSHOT 141
- 15.8.2 PRODUCT PORTFOLIO 141
- 15.8.3 RECENT DEVELOPMENT 141
  - 15.8.3.1 NEW CENTER OPENING 141
15.9 CERTARA 142
- 15.9.1 COMPANY SNAPSHOT 142
- 15.9.2 REVENUE ANALYSIS 142
- 15.9.3 PRODUCT PORTFOLIO 143
- 15.9.4 RECENT DEVELOPMENTS 143
  - 15.9.4.1 CONTRACT 143
  - 15.9.4.2 ACQUISITION 143
15.10 CLARIO 144
- 15.10.1 COMPANY SNAPSHOT 144
- 15.10.2 PRODUCT PORTFOLIO 144
- 15.10.3 RECENT DEVELOPMENT 144
  - 15.10.3.1 PRODUCT EXPANSION 144
15.11 MEDPACE 145
- 15.11.1 COMPANY SNAPSHOT 145
- 15.11.2 REVENUE ANALYSIS 145
- 15.11.3 PRODUCT PORTFOLIO 146
- 15.11.4 RECENT DEVELOPMENTS 146
  - 15.11.4.1 ACQUISITION 146
15.12 NCARDIA 147
- 15.12.1 COMPANY SNAPSHOT 147
- 15.12.2 PRODUCT PORTFOLIO 147
- 15.12.3 RECENT DEVELOPMENT 147
  - 15.12.3.1 PARTNERSHIP 147
15.13 NEXEL CO., LTD 148
- 15.13.1 COMPANY SNAPSHOT 148
- 15.13.2 PRODUCT PORTFOLIO 148
- 15.13.3 RECENT DEVELOPMENTS 148
  - 15.13.3.1 JOINT VENTURE 148
  - 15.13.3.2 PARTNERSHIP 149
15.14 PHYSIOSTIM 150
- 15.14.1 COMPANY SNAPSHOT 150
- 15.14.2 PRODUCT PORTFOLIO 150
- 15.14.3 RECENT DEVELOPMENT 150
  - 15.14.3.1 PARTNERSHIP 150
15.15 RICHMOND PHARMACOLOGY 151
- 15.15.1 COMPANY SNAPSHOT 151
- 15.15.2 PRODUCT PORTFOLIO 151
- 15.15.3 RECENT DEVELOPMENT 151
  - 15.15.3.1 EVENT 151
15.16 SGS SA 152
- 15.16.1 COMPANY SNAPSHOT 152
- 15.16.2 REVENUE ANALYSIS 152
- 15.16.3 PRODUCT PORTFOLIO 153
- 15.16.4 RECENT DEVELOPMENT 153
  - 15.16.4.1 ACQUISITION 153
15.17 SHANGHAI MEDICILON INC. 154
- 15.17.1 COMPANY SNAPSHOT 154
- 15.17.2 PRODUCT PORTFOLIO 154
- 15.17.3 RECENT DEVELOPMENTS 154
  - 15.17.3.1 PARTNERSHIP 154
  - 15.17.3.2 PARTNERSHIP 155

16 QUESTIONNAIRE 156

17 RELATED REPORTS 158

LIST OF TABLES

TABLE 1 PROPORTION OF WOMEN IN CLINICAL STUDIES, ACCORDING TO DEVELOPMENT PHASE 39
TABLE 2 PROBABILITY OF SUCCESS BY CLINICAL TRIAL PHASE TO THERAPEUTIC AREA 40
TABLE 3 MORTALITY RATES FROM CLINICAL TRIALS AND EUROPEAN SAFETY AND EXPOSURE SURVEY (ESES), DEATHS PER 100 (PYE) 40
TABLE 4 ADHERENCE RATE TO COMMON CARDIOVASCULAR MEDICATION 41
TABLE 5 PROPORTION OF WOMEN IN CLINICAL STUDIES, ACCORDING TO DEVELOPMENT PHASE 43
TABLE 6 INITIATIVES TO INCREASE ENROLLMENT IN CLINICAL TRIALS AMONG UNDERREPRESENTED POPULATIONS 45
TABLE 7 ESTIMATED COST OF CARDIAC SAFETY EVALUATION DEVICES 47
TABLE 8 MIDDLE EAST & AFRICA CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 63
TABLE 9 MIDDLE EAST & AFRICA ECG/HOLTER MEASUREMENTS IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 64
TABLE 10 MIDDLE EAST & AFRICA BLOOD PRESSURE MEASUREMENTS IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 65
TABLE 11 MIDDLE EAST & AFRICA IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 65
TABLE 12 MIDDLE EAST & AFRICA IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 66
TABLE 13 MIDDLE EAST & AFRICA HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 66
TABLE 14 MIDDLE EAST & AFRICA COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 67
TABLE 15 MIDDLE EAST & AFRICA CARDIOVASCULAR IMAGING IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 68
TABLE 16 MIDDLE EAST & AFRICA REAL TIME TELEMETRY MONITORING IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 68
TABLE 17 MIDDLE EAST & AFRICA CENTRAL OVER-READ OF ECGS IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 69
TABLE 18 MIDDLE EAST & AFRICA NON-INVASIVE CARDIAC IMAGING IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 70
TABLE 19 MIDDLE EAST & AFRICA PHYSIOLOGIC STRESS TESTING IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 70
TABLE 20 MIDDLE EAST & AFRICA THOROUGH QT STUDIES IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 71
TABLE 21 MIDDLE EAST & AFRICA TQT AND EXPOSURE RESPONSE MODELLING IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 72
TABLE 22 MIDDLE EAST & AFRICA PLATELET AGGREGATION IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 72
TABLE 23 MIDDLE EAST & AFRICA OTHERS IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 73
TABLE 24 MIDDLE EAST & AFRICA CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION) 77
TABLE 25 MIDDLE EAST & AFRICA PHASE I IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 78
TABLE 26 MIDDLE EAST & AFRICA PHASE II IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 79
TABLE 27 MIDDLE EAST & AFRICA PHASE III IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 79
TABLE 28 MIDDLE EAST & AFRICA CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION) 83
TABLE 29 MIDDLE EAST & AFRICA INTEGRATED SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 84
TABLE 30 MIDDLE EAST & AFRICA STANDALONE SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 85
TABLE 31 MIDDLE EAST & AFRICA CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION) 89
TABLE 32 MIDDLE EAST & AFRICA PHARMACEUTICALS & BIOPHARMACEUTICALS COMPANIES IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 90
TABLE 33 MIDDLE EAST & AFRICA CONTRACT RESEARCH ORGANIZATIONS IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 91
TABLE 34 MIDDLE EAST & AFRICA ACADEMIC AND RESEARCH INSTITUTE IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 91
TABLE 35 MIDDLE EAST AND AFRICA CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020-2029 (USD MILLION) 98
TABLE 36 MIDDLE EAST AND AFRICA CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 98
TABLE 37 MIDDLE EAST AND AFRICA IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 99
TABLE 38 MIDDLE EAST AND AFRICA HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 99
TABLE 39 MIDDLE EAST AND AFRICA COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 99
TABLE 40 MIDDLE EAST AND AFRICA CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION) 100
TABLE 41 MIDDLE EAST AND AFRICA CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION) 100
TABLE 42 MIDDLE EAST AND AFRICA CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION) 100
TABLE 43 SOUTH AFRICA CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 101
TABLE 44 SOUTH AFRICA IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 101
TABLE 45 SOUTH AFRICA HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 102
TABLE 46 SOUTH AFRICA COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 102
TABLE 47 SOUTH AFRICA CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION) 102
TABLE 48 SOUTH AFRICA CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION) 102
TABLE 49 SOUTH AFRICA CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION) 103
TABLE 50 SAUDI ARABIA CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 104
TABLE 51 SAUDI ARABIA IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 104
TABLE 52 SAUDI ARABIA HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 105
TABLE 53 SAUDI ARABIA COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 105
TABLE 54 SAUDI ARABIA CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION) 105
TABLE 55 SAUDI ARABIA CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION) 105
TABLE 56 SAUDI ARABIA CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION) 106
TABLE 57 U.A.E. CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 107
TABLE 58 U.A.E. IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 107
TABLE 59 U.A.E. HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 108
TABLE 60 U.A.E. COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 108
TABLE 61 U.A.E. CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION) 108
TABLE 62 U.A.E. CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION) 108
TABLE 63 U.A.E. CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION) 109
TABLE 64 ISRAEL CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 110
TABLE 65 ISRAEL IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 110
TABLE 66 ISRAEL HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 111
TABLE 67 ISRAEL COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 111
TABLE 68 ISRAEL CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION) 111
TABLE 69 ISRAEL CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION) 111
TABLE 70 ISRAEL CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION) 112
TABLE 71 EGYPT CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 113
TABLE 72 EGYPT IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 113
TABLE 73 EGYPT HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 114
TABLE 74 EGYPT COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 114
TABLE 75 EGYPT CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION) 114
TABLE 76 EGYPT CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION) 114
TABLE 77 EGYPT CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION) 115
TABLE 78 REST OF MIDDLE EAST AND AFRICA CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 116

LIST OF FIGURES

FIGURE 1 MIDDLE EAST & AFRICA CARDIAC SAFETY SERVICES MARKET: SEGMENTATION 19
FIGURE 2 MIDDLE EAST & AFRICA CARDIAC SAFETY SERVICES MARKET: DATA TRIANGULATION 22
FIGURE 3 MIDDLE EAST & AFRICA CARDIAC SAFETY SERVICES MARKET: DROC ANALYSIS 23
FIGURE 4 MIDDLE EAST & AFRICA CARDIAC SAFETY SERVICES MARKET: MIDDLE EAST & AFRICA VS COUNTRY MARKET ANALYSIS 24
FIGURE 5 MIDDLE EAST & AFRICA CARDIAC SAFETY SERVICES MARKET: COMPANY RESEARCH ANALYSIS 24
FIGURE 6 MIDDLE EAST & AFRICA CARDIAC SAFETY SERVICES MARKET: INTERVIEW DEMOGRAPHICS 26
FIGURE 7 MIDDLE EAST & AFRICA CARDIAC SAFETY SERVICES MARKET: DBMR MARKET POSITION GRID 27
FIGURE 8 MIDDLE EAST & AFRICA CARDIAC SAFETY SERVICES MARKET: MARKET END USER GRID 29
FIGURE 9 MIDDLE EAST & AFRICA CARDIAC SAFETY SERVICES MARKET: VENDOR SHARE ANALYSIS 30
FIGURE 10 MIDDLE EAST & AFRICA CARDIAC SAFETY SERVICES MARKET: SEGMENTATION 34
FIGURE 11 THE INCREASE IN DEMAND FOR CARDIAC SAFETY SERVICES ARE EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA CARDIAC SAFETY SERVICES MARKET IN THE FORECAST PERIOD OF 2022 TO 2029 35
FIGURE 12 ECG/HOLTER MEASUREMENTS SUBSTITUTE IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA CARDIAC SAFETY SERVICES MARKET IN 2022 & 2029 35
FIGURE 13 PATIENT FLOW DIAGRAM FOR ANY RANDOM DRUG 43
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST & AFRICA CARDIAC SAFETY SERVICES MARKET 51
FIGURE 15 MIDDLE EAST & AFRICA CARDIAC SAFETY SERVICES MARKET: BY SERVICES, 2021 59
FIGURE 16 MIDDLE EAST & AFRICA CARDIAC SAFETY SERVICES MARKET: BY SERVICES, 2022-2029 (USD MILLION) 60
FIGURE 17 MIDDLE EAST & AFRICA CARDIAC SAFETY SERVICES MARKET: BY SERVICES, CAGR (2022-2029) 61
FIGURE 18 MIDDLE EAST & AFRICA CARDIAC SAFETY SERVICES MARKET: BY SERVICES, LIFELINE CURVE 62
FIGURE 19 MIDDLE EAST & AFRICA CARDIAC SAFETY SERVICES MARKET: BY PHASE, 2021 74
FIGURE 20 MIDDLE EAST & AFRICA CARDIAC SAFETY SERVICES MARKET: BY PHASE, 2022-2029 (USD MILLION) 75
FIGURE 21 MIDDLE EAST & AFRICA CARDIAC SAFETY SERVICES MARKET: BY PHASE, CAGR (2022-2029) 75
FIGURE 22 MIDDLE EAST & AFRICA CARDIAC SAFETY SERVICES MARKET: BY PHASE, LIFELINE CURVE 76
FIGURE 23 MIDDLE EAST & AFRICA CARDIAC SAFETY SERVICES MARKET: BY TYPE, 2021 80
FIGURE 24 MIDDLE EAST & AFRICA CARDIAC SAFETY SERVICES MARKET: BY TYPE, 2022-2029 (USD MILLION) 81
FIGURE 25 MIDDLE EAST & AFRICA CARDIAC SAFETY SERVICES MARKET: BY TYPE, CAGR (2022-2029) 81
FIGURE 26 MIDDLE EAST & AFRICA CARDIAC SAFETY SERVICES MARKET: BY TYPE, LIFELINE CURVE 82
FIGURE 27 MIDDLE EAST & AFRICA CARDIAC SAFETY SERVICES MARKET: BY END USER, 2021 86
FIGURE 28 MIDDLE EAST & AFRICA CARDIAC SAFETY SERVICES MARKET: BY END USER, 2022-2029 (USD MILLION) 87
FIGURE 29 MIDDLE EAST & AFRICA CARDIAC SAFETY SERVICES MARKET: BY END USER, CAGR (2022-2029) 87
FIGURE 30 MIDDLE EAST & AFRICA CARDIAC SAFETY SERVICES MARKET: BY END USER, LIFELINE CURVE 88
FIGURE 31 MIDDLE EAST AND AFRICA CARDIAC SAFETY SERVICES MARKET: SNAPSHOT (2021) 93
FIGURE 32 MIDDLE EAST AND AFRICA CARDIAC SAFETY SERVICES MARKET: BY COUNTRY (2021) 94
FIGURE 33 MIDDLE EAST AND AFRICA CARDIAC SAFETY SERVICES MARKET: BY COUNTRY (2022 & 2029) 94
FIGURE 34 MIDDLE EAST AND AFRICA CARDIAC SAFETY SERVICES MARKET: BY COUNTRY (2021 & 2029) 95
FIGURE 35 MIDDLE EAST AND AFRICA CARDIAC SAFETY SERVICES MARKET: BY SERVICES (2022-2029) 96
FIGURE 36 MIDDLE EAST & AFRICA CARDIAC SAFETY SERVICES MARKET: COMPANY SHARE 2021 (%) 116